EXPERTISE - NO LONGER A SINE QUA NON FOR GUIDELINE AUTHORS?

*Quis custodiet ipsos custodes?* – *Who will guard the guards themselves?* (1)


¹ Department of Cardiology and Clinical Research, Inselspital Bern, University of Bern, Bern, Switzerland, Mount Sinai Icahn School of Medicine, New York and Jagiellonian University Krakow, Poland. ² Department of Cardiology and Clinical Research, Inselspital Bern, University of Bern, Switzerland. ³ Department of Clinical and Experimental Sciences, Clinica Medica, University of Brescia, Brescia, Italy. ⁴ Service de Néphrologie et Hypertension, Centre Hospitalier Universitaire Vaudois (CHUV), Rte du Bugnon 17, 1011, Lausanne, Switzerland. ⁵ Pacific Northwest University of Health Sciences, Yakima, WA 998908, USA. ⁶ Heart Disease Prevention Program, Division of Cardiology, Department of Medicine, C240 Medical Sciences,
University of California, Irvine, CA 92697-4079, USA. 7 Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland. 8 Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan. 9 Department of Cardiology, University of Oslo, Ulleval Hospital, Oslo, Norway. 10 Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. 11 Departments of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France. 12 Hypertension Unit, University of Ottawa Heart Institute, Ottawa, ON, Canada. 13 Department of Heart Diseases, University of Bergen, Haukeland Hospital, Bergen, Norway. 14 University of Milano-Bicocca, IRCCS Istituto Auxologico Italiano, Milano, Italy. 15 Department of Hypertension and Diabetology, Medical University of Gdansk, Poland. 16 Hypertension and Cardiovascular Research Clinic, Veterans Affairs and Georgetown University Medical Centers, Washington DC, USA. 17 Department of Cardiovascular, Neural and Metabolic Sciences, Ospedale S. Luca IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy. 18 Imperial Clinical Trials Unit, Imperial College London, London, UK. 19 Hospital Clinico Universidad de Valencia, Spain. 20 Department of Nephrology, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain. 21 Lady Davis Institute for Medical Research and Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada. 22 Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany. 23 Division of Nephrology and Hypertension, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA; American Society of Hypertension, Drexel University College of Medicine, Philadelphia, PA, USA. 24 International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London - Hammersmith
Campus, London, UK. 25 Diabetes and Cardiovascular Center, University of Missouri School of Medicine, Columbia, MO, 65212, USA; Research Service, Harry S Truman Memorial Veterans Hospital, Research Service, 800 Hospital Dr, Columbia, MO 65212, USA; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO, 65212, USA. 26 University of Leuven, Leuven, Belgium. 27 Department of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China. 28 SUNY Downstate Medical Center, Brooklyn, NY, USA. 29 University College London, and National Institute for Health Research University College London Hospitals Biomedical Research Centre, United Kingdom.

WC 1559, 1 Table

Corresponding author: Franz H. Messerli, MD, FACC, Professor of Medicine, University of Bern, Switzerland, Mount Sinai Icahn School of Medicine, New York and Jagiellonian University Krakow, Poland. Phone: +41 77 468 13 63; Fax: + 41 31 632 42 11; email: messerli.f@gmail.com
Guidelines are traditionally scripted by a panel of experts who are intimately familiar with the topic in question. Practicing physicians inherently trust guideline authors and rarely ever question their expertise, especially when guidelines are endorsed by such venerable societies as the American College of Physicians (ACP) and the American Academy of Family Practitioners (AAFP) and are published in high impact journals such as the Annals of Internal Medicine. The more than 250,000 members of the ACP and AAFP have come to expect that any set of clinically meaningful guidelines has been put together by authors who were selected because of their outstanding skills and expertise pertaining to the topic in question. Thus, there is little if any reason to voice doubt as to the validity of published guidelines.

The Free Dictionary defines expertise as “special skills or knowledge acquired by a person through education, training, or experience.” For a physician unfamiliar with the experts, there are several simple ways to get a grasp on the quality and quantity of expertise:

1. One can scrutinize the publication list of the experts, to assess how often they have been involved with the guideline topic. Any expert is expected to be well published in the specific area of the expertise.

2. One may take into account an expert’s membership in professional organizations pertaining to the subject matter. Obviously, membership and participation in annual meetings demonstrates an ongoing interest in the guideline topic.

3. One may examine whether the physician/scientist has been invited to serve on editorial boards of journals dealing with the topic in question. Being a member of an editorial board and peer reviewing submissions attest to some expertise pertaining to the guideline topic.
When one scrutinizes the authors of what is called the Joint National Committee (JNC) 8 (2), there is little doubt that most of them were indeed true experts, displaying “skills or knowledge acquired through education, training, or experience” to guide other physicians in detection, evaluation, and treatment of patients with hypertension. Many of these authors have extensively published on hypertensive cardiovascular disease, are members of professional societies and editorial boards of peer reviewed journals on hypertension (Table 1).

Such is unfortunately not the case when canvassing the authors of the recent “Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians” pertaining to “Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older” (3). Table 1 compares the authors of JNC 8 with the authors of the ACP/AAFP Guidelines pertaining to publication record on hypertension, membership in professional societies and membership of editorial boards. The highly statistically significant results mostly are self-explanatory. In fact, as per PubMed, 3 of the 7 guideline authors have never authored an article on hypertension and 1 has coauthored a single study only. Moreover, not one of the authors of the ACP/AAFP Guideline is known to be a hypertension specialist certified by the American Society of Hypertension (ASH) or even a member of ASH or of the AHA Council for High Blood Pressure. In contrast, more than half of the JNC 8 authors are certified ASH specialists and even more are ASH members. No ACP/AAFP Guideline author is currently serving on the editorial board of a journal dealing with hypertension such as Hypertension, Journal of Hypertension, American Journal of Hypertension etc., whereas the JNC 8 authors have a total of 17 editorial board memberships.

In order, not to overlook any hypertension experts we, also examined the individuals who were listed serving on the ACP Clinical Guidelines Committee from initiation of the project until its
approval. If anything, their records of the same expertise criteria is even inferior to those of the authors. One can of course argue that hypertension is a common disorder and those individuals listed as serving on the ACP Clinical Guidelines who are practicing physicians, have treated and continue to treat hypertensive patients. However, the mere fact that you know how and when to prescribe hydrochlorothiazide does not make you an expert in hypertensive cardiovascular disease.

On a somewhat positive note, the authors clearly have extensive know-how as to formalities regarding composition of guidelines and are aware of pertinent rules and regulations. Also, compared with the JNC 8 authors, the ACP/AAFP Guideline authors have a much shorter list of conflicts of interest. By no means are we suggesting that such authorship should consist of experts only, but at a minimum, experts should be part of it or at least extensively consulted. The complete absence of individuals with experience in hypertensive cardiovascular disease makes the ACP/AAFP Guidelines unacceptable to practicing physicians.

To list various deficiencies in the ACP/AAFP Guidelines is beyond the scope of this commentary. Briefly, the authors make very similar recommendations as JNC 8, which depended on evidence that was strong in itself, but not truly relevant to the guideline's most vital question: What is the optimal blood pressure treatment target in hypertensive patients aged 60 or over?

Importantly new outcomes evidence and analyses available since JNC 8 was published, appear to have been discounted by the ACP/AAFP Guideline authors. Of concern is that SPRINT-Elderly data or any of the subsequent analyses have been ignored. Clearly these findings are seminal to the above question (4,5).

Of note, the meta-analysis (6) on which the ACP/AAFP Guidelines are based, although supposedly dealing with adults aged 60 years or older, included randomized trials of patients with a mean age of at least 60 years. This means that this meta-analysis (and the resulting guidelines)
were based on findings from numerous patients who were below that age limit. In addition, as
pointed out by Bangalore (S. Bangalore, personal communication), one of the issues with the
underlying meta analysis pertains to the problematic terminology of "intensive" and "standard".
The "intensive" arm of ADVANCE (Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation) (~134 mm Hg) achieved similar BP control
as the "standard" arm of ACCORD (The Action to Control Cardiovascular Risk in Diabetes
Study Group) or SPRINT (Systolic Blood Pressure Intervention Trial) (133 mm Hg) and
therefore combining this in a meta analysis is inappropriate.

Regarding safety, the ACP/AAFP Guidelines fail to identify angioedema as a rare but potentially
fatal adverse event of angiotensin converting enzyme inhibitors (7, 8). African American patients
are at a particularly high risk of angioedema with this drug class (8, 9, 10). Since the angioedema
may manifest itself months after initiation of therapy, not uncommonly neither patient nor
physician connect the dots between the antihypertensive medication and periodic swelling of lips,
tongue and larynx. Not to even list angioedema as an adverse event is a most troubling omission.
We are not privileged to know who selected the authors for the ACP/AAFP Guidelines, nor do
we have access to selection criteria. In most US and international guidelines (2, 11, 12) selection
has been expertise based. However, as illustrated by ACP/AAFP Guidelines, expertise no longer
seems to be a prerequisite, or sine qua non, for authoring guidelines for practicing physicians. If
there were selection criteria for the authors of these hypertension guidelines, they must have been
other than “special skills or knowledge acquired by a person through education, training, or
experience.”
Disclosures

F.H.M.: Consultant or advisory relationships with the following companies: Daiichi-Sankyo, Pfizer, Servier, WebMD, Ipca, American College of Cardiology, Menarini, Relypsa, Sandoz.


G.P.: Honoraria for lecturing from Pfizer, Menarini, Daiichi Sankyo, Servier, Omron Healthcare.

N.P.: In the field of hypertension and in the last 2 years, Prof. Poulter has received speaker honoraria from Servier, Sandoz and Napi Pharmaceuticals. His unit received research funds and he has received fees for attending ad hoc advisory boards from Servier.
S.F.R.: Consultant or advisory relationships with the following companies: Servier, Menarini

E.L.S.: Dr. E.L. Schiffrin declares the following conflicts of interest: Research grant from Canadian Institutes of Health Research (CIHR) and a Canada Research Chair from CIHR/Government of Canada, a discovery grant from Servier France, and honoraria from Novartis USA and Servier Canada. M.W.: Consultant for Eli Lilly, Allergan, Novartis, Medtronic, ReCor, Ablative Solutions, Boston Scientific, Astellas; serves as a speaker for Merck and Menarini, and provides research services to Astra Zeneca. B.W.: In the field of hypertension and in the last 2 years, BW has received speaker honoraria from Novartis, Boehringer Ingelheim, Servier, Daiichi Sankyo, and Fukuda Denshi.

References

1. Decimus Iunius Iuvenalis (Juvenal), 1st-2nd century AD, Satire VI, lines 347-348


**Table 1:** Comparison of publications, Society of Hypertension certification and membership, and Editorial Board Membership (as per 01/2017)

<table>
<thead>
<tr>
<th></th>
<th>No. of Publications on Hypertension*</th>
<th>Society certified specialist†</th>
<th>Society membership‡</th>
<th>Editorial Board Membership§</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNC 8</td>
<td>39 (5.5-121)</td>
<td>8</td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>No. of authors=17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACP/AAFP</td>
<td>0.5 (0-2.5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No. of authors=6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associated members</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>ACP/AAFP No. = 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013 ESC/ESH</td>
<td>98 (40.5-197)</td>
<td>17</td>
<td>18</td>
<td>23</td>
</tr>
<tr>
<td>No. of authors=25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Median (interquartile range)
‡ American Society of Hypertension (ASH) and European Society of Hypertension (ESH), respectively